Basic Information
| Drug ID | DDPD08869 |
|
| Drug Name | Tesamorelin | |
| Molecular Weight | 5005.76 | |
| Molecular Formula | C216H360N72O63S | |
| CAS Number | 218949-48-5 | |
| SMILES | CC\C=C\CC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(N)=O | |
| External Links | ||
| DRUGBANK | DB08869 | |
| PubChem Compound | 56928011 | |
| PDR | 3656 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
Not Available
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Reference |
|---|---|---|---|---|---|---|
| Bioavailability | 4.0 | % | <4 | % | subcutaneous injection, SC; normal,healthy; | DRUGBANK |
| Volume of Distribution | 9.4 | L/kg | 9.4±3.1 | L/kg | normal,healthy; patients; | DRUGBANK | Volume of Distribution | 10.5 | L/kg | 10.5±6.1 | L/kg | AIDS,HIV; patients; | DRUGBANK |
| Half-life | 0.43 | h | 26 | min | normal,healthy; | DRUGBANK | Half-life | 0.63 | h | 38 | min | AIDS,HIV; patients; | DRUGBANK |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for adults | 1.4 | mg/day | 1.4 | mg/day | subcutaneous injection, SC | Egrifta | tesamorelin | PDR |
| Max dose for adults | 2.0 | mg/day | 2 | mg/day | subcutaneous injection, SC | Egrifta | tesamorelin | PDR |
| Max dose for geriatric | 1.4 | mg/day | 1.4 | mg/day | subcutaneous injection, SC | Egrifta | tesamorelin | PDR |
| Max dose for geriatric | 2.0 | mg/day | 2 | mg/day | subcutaneous injection, SC | Egrifta | tesamorelin | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1